We verified both single-agent efficacy of the two drugs as well as the apoptosis-inducing potency of the combination across a panel of MYCN-amplified neuroblastoma cells compared with both the MYCN-WT neuroblastoma cells and the RPE-1 cell line, where it was ineffective (Figure 5A, 57.6 ± 8.1 versus 5.8 ± 2.9, Student's t test, p = 0.0015). Here, MYCN is linked to neuroblastoma.